1. Home
  2. IMTE vs AZTR Comparison

IMTE vs AZTR Comparison

Compare IMTE & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integrated Media Technology Limited

IMTE

Integrated Media Technology Limited

HOLD

Current Price

$0.65

Market Cap

2.4M

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.21

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMTE
AZTR
Founded
2008
2014
Country
Australia
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
IMTE
AZTR
Price
$0.65
$0.21
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
3.1M
1.8M
Earning Date
10-22-2024
02-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$72,641.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.19
52 Week High
$3.17
$2.97

Technical Indicators

Market Signals
Indicator
IMTE
AZTR
Relative Strength Index (RSI) 41.68 27.99
Support Level $0.58 $0.19
Resistance Level $0.67 $0.22
Average True Range (ATR) 0.09 0.02
MACD -0.02 -0.00
Stochastic Oscillator 6.32 2.99

Price Performance

Historical Comparison
IMTE
AZTR

About IMTE Integrated Media Technology Limited

Integrated Media Technology Ltd is mainly engaged in the business of manufacture and sale of nano-coated plates for filters, the manufacture and sale of electronic glass, Halal certification and distribution of Halal products, and new energy products and services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: